The first drugs approved by regulatory agencies for MS are Interferons-β (IFN-β), including five preparations used for relapsing-remitting multiple sclerosis (RRMS) and modestly reducing the frequency of relapses [97]. This evidence concerns the gene IFNB1 and relapsing-remitting multiple sclerosis.